Antipollution decree in China shutters drug manufacturing in Shijiazhuang until year-end

Drug manufacturing will be halted until year-end in the northern city of Shijiazhuang as part of a crackdown on pollution.

Chinese authorities have halted drug manufacturing in the northern city of Shijiazhuang as part of a crackdown on pollution. The shuttering of the three plants is expected to last until year-end.

Other manufacturing shutdowns in the city include steel, cement, and coal-electricity plants, authorities said.

The crackdown on air pollution is part of the government’s efforts over the past few years to reduce the blankets of smog that settle over China’s northern cities during the winter and have been known to be hazardous to health as well as create traffic hazards, Reuters reported.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Three drug manufacturers in Shijiazhuang were shuttered and halted trading of their shares on the Hong Kong stock market: North China Pharmaceutical, CSPC Pharmaceutical Group and SSY Group. The city is located about 200 miles from Beijing.

"The group has been actively cooperating with the government on environmental protection work and is making an application to the Shijiazhuang municipal government for permission to continue its normal pharmaceutical production in Shijiazhuang," CSPC said in a filing to the Hong Kong stock exchange.

Read more on

Suggested Articles

Astellas buys gene therapy player Audentes for $3 billion. Keytruda and Opdivo fail to win coverage in China. Hanmi inks I-O deal with Rapt.

Higher operating costs were behind a 17% slide in pretax profits last year at Allergan’s Mayo, Ireland, facility that produces Botox.

After a global scare over Zantac contamination, generic metformin could be next in line as regulators test for possible carcinogen contamination.